LLY

1,044.83

-1.4%↓

JNJ

209.42

-2.34%↓

ABBV

222.58

-2.02%↓

UNH

332.12

-2.75%↓

AZN

90.67

-0.71%↓

LLY

1,044.83

-1.4%↓

JNJ

209.42

-2.34%↓

ABBV

222.58

-2.02%↓

UNH

332.12

-2.75%↓

AZN

90.67

-0.71%↓

LLY

1,044.83

-1.4%↓

JNJ

209.42

-2.34%↓

ABBV

222.58

-2.02%↓

UNH

332.12

-2.75%↓

AZN

90.67

-0.71%↓

LLY

1,044.83

-1.4%↓

JNJ

209.42

-2.34%↓

ABBV

222.58

-2.02%↓

UNH

332.12

-2.75%↓

AZN

90.67

-0.71%↓

LLY

1,044.83

-1.4%↓

JNJ

209.42

-2.34%↓

ABBV

222.58

-2.02%↓

UNH

332.12

-2.75%↓

AZN

90.67

-0.71%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

548.66 -1.23

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

544.23

Max

560.22

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
EPS	-4.956
Winstmarge	-39.75
Werknemers	528
EBITDA	-75M -114M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+0.05% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.7B 13B
Vorige openingsprijs	549.89
Vorige sluitingsprijs	548.66

Nieuwssentiment

By Acuity

29%

71%

68 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 dec 2025, 17:39 UTC

Belangrijke Marktbewegers

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15 dec 2025, 23:44 UTC

Marktinformatie

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15 dec 2025, 23:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

15 dec 2025, 23:38 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15 dec 2025, 22:19 UTC

Marktinformatie

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15 dec 2025, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

15 dec 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15 dec 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15 dec 2025, 21:22 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

ServiceNow Completes Acquisition Of Moveworks >NOW

15 dec 2025, 21:00 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 dec 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 dec 2025, 20:36 UTC

Marktinformatie

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15 dec 2025, 20:31 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15 dec 2025, 20:27 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15 dec 2025, 20:15 UTC

Marktinformatie

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15 dec 2025, 19:22 UTC

Marktinformatie

Gold and Silver Gain to Start Week -- Market Talk

15 dec 2025, 18:37 UTC

Marktinformatie

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15 dec 2025, 18:29 UTC

Marktinformatie

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15 dec 2025, 17:58 UTC

Marktinformatie

Canada Housing Market In Search Of a Bottom -- Market Talk

15 dec 2025, 17:36 UTC

Marktinformatie

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15 dec 2025, 17:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 dec 2025, 17:36 UTC

Winsten

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15 dec 2025, 17:30 UTC

Acquisities, Fusies, Overnames

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

0.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 571.73 USD 0.05%

Hoogste 670 USD

Laagste 445 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

68 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.